Tech Company Financing Transactions
HDL Therapeutics Funding Round
HDL Therapeutics closed a $5.7 million Series C investment round on 5/11/2017. Investors included private investors.
Transaction Overview
Company Name
Announced On
5/11/2017
Transaction Type
Venture Equity
Amount
$5,708,455
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 57 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
46701 Commerce Center Dr.
Plymouth, MI 48170
USA
Plymouth, MI 48170
USA
Phone
Email Address
Not Recorded
Overview
We are a privately held cardiovascular device company and a leader in the field of reversing coronary atherosclerosis. Our innovative acute care therapeutic device called PDS-2� System transforms a patient's own plasma into an atherosclerostic reversal agent using our patented technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roger Newton
Browse more venture capital transactions:
Prev: 5/11/2017: Intrinsic Therapeutics venture capital transaction
Next: 5/11/2017: nLight venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs